2nd Edition of World Congress on

Immunology & Oncology

Theme: Explore the Possibilities in the Field of Oncology and Immunology

Event Date & Time

Event Location

Paris, France

18 years of lifescience communication


Previous Conference Performers / Professionals From Around The Globe

Conference Speaker

Wassil Nowicky

President Ukrainian Anti-Cancer Institute

Conference Speaker

Weisi Yan

Director CyberKnife Program, University of South Alabama

Conference Speaker

Donglu Shi

Professor University of Cincinnati

Conference Speaker

Igor Smit


Conference Speaker

Rosario Davalos


Conference Speaker

Jose Antonio Matute

Submedical director

Conference Speaker

George Kunudji


Conference Speaker

Marjan Jalali Mehr


Conference Speaker

Kamlesh Guleria

Assistant Professor

Conference Speaker

Kenji Ohe


Conference Speaker

Slobodníková Jana

Assistant Professor

Conference Speaker

Dina Ron


Tracks & Key Topics

Immuno Oncology 2019

About Conference

The EuroSciCon welcomes you to attend the Immunology & Oncology 2019 focus on Current Advancements and its Applications in Immunology and Oncology from April 18-19 in Paris, France The theme of this year’s meeting is “Explore the Possibilities in the Field of Oncology and Immunology " which will provide an international platform for discussion of present and future challenges in Immunology, Immuno Oncology education, continuing education and expertise meeting. World-leading health Immunologists, Oncologists, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and emerging research.

What’s New

Immunology & Oncology 2019 includes international attendee workshops, lectures and symposia, including a designated registration area, a refreshment break and gala lunch. Immunologists & Oncologists can join the EuroSciCon as an international member to receive discounts on registration. So come and join leading experts and allied professionals from April 18-19, 2019 in Paris, France to keep up with the rapidly accelerating pace of change that is already having an impact on the field of Cancer & Immuno Oncology and will continue to in the future.

The scientific program includes Keynote & Plenary talks, Video Presentations, Poster Presentations and E-Posters. Furthermore, oral communications of (post)doctoral junior scientists will be considered. It is the goal of the organizers to make this meeting an event of scientific excellence, attractive to both industrial and academic scientists in Oncology & Immuno Oncology and its advancements.

EuroSciCon is the longest running independent life science events company with a predominantly academic client base. Our multi-professional and multi-speciality approach creates a unique experience that cannot be found with a specialist society or commercially.

Opportunities for Conference Attendees

For Researchers &Faculty:

  • Speaker Presentations
  • Poster Display
  • Symposium hosting
  • Workshop organizing

For Universities, Associations & Societies:

  • Association Partnering
  • Collaboration proposals
  • Academic Partnering
  • Group Participation

For Students & Research Scholars:

  • Poster Competition (Winner will get Best Poster Award)
  • Young Researcher Forum (YRF Award to the best presenter)
  • Student Attendee
  • Group Registrations

For Business Delegates:

  • Speaker Presentations
  • Symposium hosting
  • Book Launch event
  • Networking opportunities
  • Audience participation

For Companies:

  • Exhibitor and Vendor Booths
  • Sponsorships opportunities
  • Product launch
  • Workshop organizing
  • Scientific Partnering
  • Marketing and Networking with clients

Euroscicon organizes International Oncology Meetings annually across Europe, Austria, Ireland, Germany, France, Liechtenstein, Lithuania, Finland, Luxembourg, Hungary, Italy, Norway, Poland, Denmark, Macedonia, Greece, Portugal, Romania, Czech Republic, Switzerland, United Kingdom, Belgium, Scotland, Latvia, Ukraine, Sweden, Denmark, Spain, Netherlands, Russia, Bulgaria, France, with solitary subject of quickening logical revelations.


  • Antibody Therapy of Cancer
  • Anti-Cancer Drugs
  • Biochemistry of Cancer
  • Breast Cancer
  • Cancer Biomarkers
  • Cancer Cell Biology
  • Cancer Staging
  • Cancer Trends and Opportunities
  • Cardio-Oncology
  • Combining Cancer Immunotherapies
  • Endocrine and Neuroendocrine Tumors
  • Gastrointestinal Cancers
  • Head and neck cancers
  • Hematologic Cancers
  • Immuno Oncology
  • Immuno-Oncology Studies
  • Medical Oncology
  • Neuro Immunology
  • Neuro-oncology
  • Nuclear Medicine
  • Orbital and adnexal cancers
  • Radiation Oncology
  • Reproductive Cancer
  • Surgical Oncology
  • Tumour Immunotherapy Research
  • Types of Cancer




 Track 1: Immuno-Oncology Studies

The immune system is the body’s natural defence system. It is a collection of organs, cells and special molecules that help protect you from infections, cancer and other diseases. Immuno-oncology therapies activate our immune system, making it able to recognize cancer cells and destroy them. Breast cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development. Lung cancer surgery carries risks, including bleeding and infection. Clinical trials are studies of experimental lung cancer treatments. Adult central nervous system tumour is a disease in which abnormal cells form in the tissues of the brain and/or spinal cord. A tumour that starts in another part of the body and spreads to the brain is called a metastatic brain tumour

Track 2: Tumour Immuno Therapy Research

Our immune system protects us from diseases, including cancer. Normally our immune system spots and destroys faulty cells but sometimes these cells can escape detection and develop into tumours. Immunotherapy is a relatively new form of treatment that re-awakens the immune system so it can fight cancer. Engaging the immune system in this way might have long-lasting benefits if the immune system can ‘remember’ cancer and stop it coming back.

Track 3: Surgical Oncology

Surgery is the main treatment in nearly every case of cancer, and it is the main treatment for both pheochromocytoma and Merkel cell cancer. During surgery, the doctor removes a tumour along with a small border of healthy tissue around a tumour, called a margin. For pheochromocytoma, laparoscopic surgery may be performed. Laparoscopic surgery is a less invasive type of surgery that uses three or four small incisions instead of one large incision. A thin, lighted tube called a laparoscope that is attached to a video camera is inserted through one opening to guide the surgeon. Surgical instruments are inserted through the other openings to perform the surgery. If removing the tumour using surgery is not possible, it is called an inoperable tumour, and the doctor will recommend another type of treatment. The patient candidate for surgery does not depend on factors such as the type, size, location, grade and stage of the Tumor along with the consideration of the general health factors like age, physical fitness and other coexisting medical conditions. Surgery will be combined with other Cancer treatments, such as chemotherapy, Radiation therapy or hormone therapy in some Cases.

Track 4: Reproductive Cancer

Reproductive Cancers are those Cancers that occur in the reproductive organs of both Women and Men. In Women, these are Cancers that commonly occur in the breast, cervix, vulva, endometrium or Ovaries. In men, reproductive Cancer can be found in the prostate, testicles, and penis.

Track 5: Radiation Oncology

Radiation medical speciality is to embrace all aspects of analysis which influences the treatment of cancer using radiation. The sphere of radiation medical speciality covers the admixture of action therapy into multimodal treatment approaches. External beam radiation is delivered outside the body. This includes leading high-energy radiation beams at the area being targeted among the body victimization varied radiation machines. Brachytherapy is radiation applied directly to the target. It is extremely effective as the radiation is focused on the target diseased site instead of healthy closed organs. Radioimmune therapy (RIT) uses protein with specificity for a growth- associated substance tagged with a radionuclide to deliver cytotoxic radiation to a tumour cell. General action therapy uses radioactive medication to treat cancer consistently, within which the radioactive substance travels through the bloodstream to achieve cells inside the body.

Track 6: Orbital and adnexal cancers

Cancers of the orbit and adnexa develop from tissues such as muscle, nerve, and skin around the eyeball and are like their counterparts in other parts of the body.

Track 7: Nuclear Medicine

Nuclear medicine imaging uses small amounts of radioactive materials called radiotracers that are typically injected into the bloodstream, inhaled or swallowed. The radiotracer travels through the area being examined and gives off energy in the form of gamma rays which are detected by a special camera and a computer to create images of the inside of your body. Nuclear medicine imaging provides unique information that often cannot be obtained using other imaging procedures and offers the potential to identify the disease in its earliest stages.



Track 8: Neuro-oncology

Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life-threatening (astrocytoma, glioma, glioblastoma, multiform, ependymoma, pontine glioma, and brain stem tumours are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade (highly anaplastic) astrocytoma are among the worst. In these cases, if untreated lifespan usually amounts to only a few months, and survival with current radiation and chemotherapy treatments may extend that time from around a year to a year and a half, possibly two or more, depending on the patient's condition, immune function, treatments used.

Track 9: Neuro Immunology

Neuroimmunology is a field combining neuroscience, the study of the nervous system, and immunology, the study of the immune system. Neuroimmunologists seek to better understand the interactions of these two complex systems during development, homeostasis, and response to injuries. A long-term goal of this rapidly developing research area is to further develop our understanding of the pathology of certain neurological diseases, some of which have no clear aetiology. In doing so, neuroimmunology contributes to the development of new pharmacological treatments for several neurological conditions. Many types of interactions involve both the nervous and immune systems including the physiological functioning of the two systems in health and disease, malfunction of either and or both systems that lead to disorders, and the physical, chemical, and environmental stressors that affect the two systems on a daily basis. We know both the nervous system and the immune system plays a major role in humans life. One as a signal system and one as a protective system.

Track 10: Medical Oncology

Medical oncology is the analysis of cancer with medicine, made up of chemotherapy, surgical oncology is the surgical aspects of cancer including biopsy, staging, and surgical resection of tumours, and radiation oncology is the analysis of cancer with therapeutic radiation. Medical Oncology is usually working in conjunction with Surgical Oncology or Radiation Oncology to give the best clinical outcomes. We determine the right treatment plan for each individual based on various factors as a stage of cancer, the extent of the damage, other medical conditions, and location within the body. These treatment plans contain any combination of the following: Chemotherapy, Radiation Therapy and Surgery.

Track 11: Hematologic Cancers

Hematologic cancers affect the production and function of ones’ blood cells. Most of these cancers originate in the bone marrow where blood is produced. Stem cells in the bone marrow mature and develop into three types of blood cells: red blood cells, white blood cells, or platelets. In most blood cancers, the normal blood cell development process is interrupted by uncontrolled growth of an abnormal type of blood cell. These abnormal blood cells, or cancerous cells, prevent the blood from performing many of its functions, like fighting off infections or preventing serious bleeding.

Track 12: Head and neck cancers

Head and Neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also develop in the salivary glands, but salivary gland cancers are relatively uncommon. Salivary glands contain different types of cells that can become cancerous, so there are many different types of salivary gland cancer. Cancers of the head and neck are further categorized by the area of the head or neck in which they begin from the Oral cavity, Pharynx, Larynx, Para-nasal sinuses and Nasal cavity, Salivary glands.

Track 13: Gastrointestinal Cancers

Gastro-Intestinal (GI) Cancer is a term for the group of cancers that affect the digestive system. The known risk factors for gastrointestinal cancers currently include smoking, alcohol consumption and obesity, asbestos etc. This includes cancers of the Esophagus, Gallbladder, Liver, Pancreas, Stomach, Small intestine, Bowel (large intestine or Colon and Rectum), and Anus

Track 14: Endocrine and Neuroendocrine Tumors

An endocrine tumour is a growth that affects the parts of the body that secrete hormones. Because an endocrine tumour arises from cells that produce hormones, the tumour itself can produce hormones. These hormones are produced in excessive amounts by endocrine tumours and then released into the blood. The excessive amounts of hormones in the blood produce marked abnormal effects on the body. A neuroendocrine tumour begins in the area showing a combination of hormone-producing endocrine cells and nerve cells. Neuroendocrine cells are found throughout the body in organs such as the lungs and gastrointestinal tract, including the stomach and intestines. Neuroendocrine cells perform specific functions, such as regulating air and blood flow through the lungs and controlling how quickly food moves through the gastrointestinal tract. They are other types of tumours in endocrine and neuroendocrine tumours.

Track 15: Cardio-Oncology

Cardio-oncology is the intersection of heart conditions in patients who have been treated for cancer. Cardiologists can assess patients for potential risk of developing heart conditions if patients take certain types of cancer drugs, or following radiation treatment to the chest. They also help oncologists protect their patients during treatment by closely watching the heart and recognizing heart trouble early in treatment.

Track 17: Cancer Trends and Opportunities

Doctors and scientists are always looking for better ways to treat patients with a tumour. To make scientific advances, doctors create research studies involving volunteers, called clinical trials. Many clinical trials are focused on new treatments, evaluating whether a new treatment is safe, effective, and possibly better than the current (standard) treatment. These types of studies evaluate new drugs, different combinations of existing treatments, new approaches in radiation therapy or surgery, and new methods of treatment. Patients who participate in clinical trials are often among the first to receive new treatments before they are widely available. However, there is no guarantee that the new treatment will be safe, effective, or better than a standard treatment. There are also clinical trials that study new ways to ease symptoms and side effects during treatment and managing the late effects that may occur after treatment.

Track 19: Cancer Staging

Cancer staging is the process of determining how much cancer has spread out inside the body and where it is located. Staging describes the severity of an individual's cancer based on the magnitude of the original (primary) a tumour as well as on the extent cancer has spread in the body. Understanding the stage of cancer helps doctors to develop a prognosis and design a treatment plan for individual patients.

Track 18: Cancer Cell Biology

The genetic changes that contribute to cancer tend to affect three main types of genes - proto-oncogenes, tumour suppressor genes, and DNA repair genes. These changes are sometimes called “drivers” of cancer. Proto-oncogenes are involved in normal cell growth and division. However, when these genes are altered in certain ways or are more active than normal, they may become cancer-causing genes (or oncogenes) allowing cells to grow and survive when they should not. Tumour suppressor genes are also involved in controlling cell growth and division. Cells with certain alterations in tumour suppressor genes may divide in an uncontrolled manner. DNA repair genes are involved in fixing damaged DNA. Cells with mutations in these genes tend to develop additional mutations in other genes. Together, these mutations may cause the cells to become cancerous. The process by which cancer cells spread to other parts of the body is called metastasis. Metastatic cancer spreads from the part of the body where it originated (the primary site) to other parts of the body. A risk factor is anything that increases a person’s chances of developing a Tumor. Although factors often influence the development of a tumour, most do not directly cause it. Some people with several risk factors never develop a tumour, while others with no known risk factors do. Some risk factors are as Age, Gender, Race/Ethnicity, Family history, Immune system suppression, arsenic exposure. Generally, the cause of Cancer is unknown. People who have one of the rare family syndromes have a higher risk of developing Tumors.

Track 19: Cancer Biomarkers

In cancer research and medicine, biomarkers are used in three primary ways:

To help diagnose conditions, as in the case of identifying early-stage cancers (Diagnostic)

To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)

To predict how well a patient will respond to treatment (Predictive)

Track 20: Breast Cancer

Breast cancer can begin in different areas of the breast; the ducts, the lobules, or in some cases, the tissue in between. In this section, we could include the different types of breast cancer, including non-invasive, invasive, recurrent, and metastatic breast cancers. Breast cancer is a phenomenon that can even occur in men. Breast tissue contains fat and connective tissue, lymph nodes and blood vessels, they are made up of glands called tubules that can produce milk and thin tubes called ducts that carry the milk to the nipple. The most common type of breast Cancer is Ductal Carcinoma. Breast Cancer can also begin in the cells of the lobules in other tissues in the breast.

Track 21: Biochemistry of Cancer

There is a great deal of research investigating the mechanisms of how drugs are metabolized and absorbed by the body's cells. Growing knowledge in this field provides the foundations for improving the anticancer potential for existing drugs and for developing new 'designer' drugs. Other work includes research into the mechanisms of drug resistance.

Track 22: Anti-Cancer Drugs

Anticancer drug, also called antineoplastic drug, any drug that is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones. In addition, there are a number of drugs that do not fall within those classes but that demonstrate anticancer activity and thus are used in the treatment of malignant disease. Chemotherapy is the use of anticancer drugs designed to slow or stop the growth of rapidly dividing cancer cells in the body.

Track 23: Antibody Therapy of Cancer

Antibody marks the cancer cell and makes it easier for the immune system to find. The monoclonal antibody drug rituximab (Rituxan) attaches to a specific protein (CD20) found only on B cells, one type of white blood cell. Certain types of lymphomas arise from these same B cells. Monoclonal antibodies can also function by attenuating hyperactive growth signals neoangiogenesis. A monoclonal antibody can be conjugated to a radioactive particle that will ensure directed delivery to the cancer cell and slow and long release of the radiation, hence maximizing chances of the positive outcome and minimizing non-specific damaging exposure to radiation.

Track 24: Combining Cancer Immunotherapies

Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumour cell growth and survival. These drugs can arrest tumour progression and induce striking regressions in molecularly defined subsets of patients. Indeed, the first small molecule targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of chronic myelogenous leukaemia patients. Further research into the underlying genetic pathways driving tumour proliferation uncovered additional oncoproteins that are critical for tumour maintenance, such as the epidermal growth factor receptor (EGFR), BRAF, KIT, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib, small molecule inhibitors of these kinases have effectuated impressive tumour responses in selected patients, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drug-mediated inhibition. Accordingly, targeted therapies may elicit dramatic tumour regressions, but persistence is generally short-lived, limiting the overall clinical benefit.

Market Report

Immunology deals with the study of development, anatomy functions and malfunctions of the immune system, which are fundamental to understand the human disease. The immune system is made up of many types of molecules and cells that are distributed in every tissue of the body, as well as specialized lymphoid organs, which act in a coordinated manner to prevent microbial infections, to initiate repair of damaged tissues and to suppress the growth of tumours. The immune system normally recognizes and responds to foreign molecules or damaged self, but not healthy host cells and tissues. The innate system of immunity is on evolutionary terms, the older system that forms the first line of defence. It is non-specific and the resistance is static. This includes physical defences such as skin & epithelial surfaces, cilia, commensal flora, acidic gastric contents, fever and some others are biochemical defences such as acute phase reactants and complement, soluble - lysozyme, interferons, fibronectin. Cellular components include natural killer cells and RES phagocytes.

Scope and Importance:

According to the journal published by Biomed Central, rotavirus infection the leading cause of severe dehydrating diarrhoea among children worldwide. Every year rotavirus infection causes an estimated 111 million diarrhoea episodes leading to 2 million hospitalization cases and 400,000 deaths of children under 5 years. Out of all these 82% occur in children in the poorest countries in Asia and Africa. As per Centers for Disease Control and Prevention (CDC), chronic HBV affected almost 1.4 million of the US population in 2011 and acting as thmajor public health challenge. In past couple of years, outbreaks for different infections have deteriorated the situation. All these reports direct towards the increasing need for immunological diagnosis and treatment for infections across the world. Therefore the market for this infection immunology may grow with significant rate in near future. On the other hand, the high cost involved and limited reach of this technology may hinder the growth of the market. 

However, the growth of the market may be significant in emerging economies in Asia and Africa considering high incidence and prevalence rate for infections. This market can also be segmented according to various categories of infections such as hepatitis viruses, retroviruses and other infections. The market has different classes of products used such as reagents, diagnostic kits, instruments and others. 

Target Audience

  • Immunology  and Molecular Biology Students, Scientists
  • Immunology and Biochemistry Researchers
  • Immunology, Microbiology Faculty
  • Young Researchers
  • Medical Colleges, Hospitals
  • Physicians/Consultants
  • Geneticist, Bioinformatician
  • Immunology, Cellular Biology Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Manufacturing Medical Devices Companies

Precision Medicine Market size was over USD 39 billion in 2015 and is anticipated to grow at 10.5% CAGR from 2016 to 2023.

Europe precision medicine market size, by application, 2013 - 2023 (USD Million)

Statistics of Physicians, Researchers and Academicians working on Molecular Medicine and Immunology section.

Academia       35%

Researchers    35%

Physicians      25%

Others             5%

Immunology Drug Market: Overview

Development of some new drugs with success rate is expected to offer the good opportunity for immunology drug market. Wide-ranging scope of Immuno-oncology agents in different cancer treatments would provide the maximum share to immunology drug market in the forecast period. pharmaceutical companies and R&D are showing increased interest in this field and is expected to offer better potential for immunology drug market. Companies involved in partnership and R&D for efficient technologies are some of the latest trends that have been observed in immunology drug market. Currently, most of the immunology drugs are in clinical trial and are expected to rise the immunology market after clearance or success of these products from clinical trials. 

Growth rate of Immunology research

A new report from business intelligence provider GBI Research - Global Immunology Market to 2022 - states that the global immunology treatment market is set to expand from the $61.5 billion in 2015 to an estimated $74.2 billion in 2022, despite the imminent expiry of a host of immunology treatments.

Immunology Drug Market: Key Market Participants

Currently various established companies in diagnostic and healthcare segment catering varied range of products such as reagents, test kits and instruments in this market out of which companies such as F. Hoffmann-La Roche Ltd., Abbott Laboratories, Shanghai Kehua Bio-engineering Co., Ltd, Trans Asia Bio-Medicals Ltd, Span Diagnostics Ltd, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc. are leading contributors in reagents and test kits, on the other hand Siemens Healthcare and PerkinElmer, Inc. are major companies in Instruments segment.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

·         North America 

·         Asia Pacific 

·         Europe

·         Rest of the World

Major Hospitals in Europe

  • Assistance Publique Hôpitaux de Paris
  • University Clinic Heidelberg Universittsklinikum Heidelberg
  • Erasmus Medisch Centrum Universitait Medisch Centrum Rotterdam
  • Asklepios Klinikum Bad Abbach
  • Leiden University Medical Center / Leids Universitair Medisch Centrum
  • Centre Hospitalier Universitaire Vaudois Lausanne
  • Hôpitaux Universitaires de Geneve
  • Universitätsklinikum Hamburg Eppendorf
  • Universitätsklinikum und Medizinische Fakultät Tübingen
  • Sahlgrenska University Hospital
  • Universitätsklinikum Freiburg
  • Universitätsklinikum Jena Klinikum der Friedrich Schiller Universität
  • Klinik und Poliklinik für Hals Nasen Ohrenheilkunde Ludwig Maximilians Universität München
  • Universitair Ziekenhuis Leuven

Top Global Immunology Universities

  • Harvard University
  • University of California--San Francisco
  • Stanford University
  • Yale University
  • Johns Hopkins University
  • Washington University in St. Louis
  • Duke University
  • University of Pennsylvania
  • University of Texas Southwestern Medical Center-Dallas

Top Companies

  • Actelion
  • Agilent
  • Alexion
  • Amgen
  • AstraZeneca
  • Bayer
  • Biogen
  • BioMarin
  • Bristol-Myers Squibb
  • Celgene
  • Daiichi Sankyo
  • Gilead Sciences
  • Glaxo Smith Kline
  • Illumina
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Regeneron
  • Roche
  • Sanofi Genzyme
  • Takeda
  • Vertex

Learn More



List of major Universities related to Oncology  in the USA:

Stanford University| California | Duke University| North Carolina | University of Chicago| Chicago | Vanderbilt University| Tennessee | Georgetown University| Washington | University of Michigan-Ann Arbor| Michigan | University of Southern California| Los Angeles | Wake Forest University| North Carolina | University of Wisconsin-Madison| Wisconsin| Madison | University of Miami| Florida | University of the Sciences| Pennsylvania University of Utah| Utah | University of Arizona| Arizona | University of Toledo| Ohio | Wayne State University| Michigan

List of major Universities related to Oncology  in Europe:

Kingston University Life Sciences| England | University of Birmingham School of Life Sciences| England | Brunel University| London | Cardiff University| Wales ||  University of Edinburgh Scotland Newcastle University Northern Northern Institute for Cancer Research| England | University of Bradford England | University of Bristol| England University of Buckingham| England | University of Cambridge| England | University College Dublin| Republic of Ireland | Edge Hill University| England | Harper Adams University| England | University of Hull| England

List of major Universities related to  Oncology in Asia:

University of Tokyo| Tokyo | National University of Singapore| Singapore |  Kyoto University| Tokyo| University of Hong Kong| Hong Kong | Peking University| China | Seoul National University| South Korea | National Taiwan University| Taiwan| Osaka University| Japan | Tsinghua University| China | The Chinese University of Hong Kong| Hong Kong | Fudan University| China Taipei Medical University| Taiwan | Mahidol University| Thailand | Tohoku University| Japan| Kyushu University| Japan | University Malaya| Malaysia | Indian Institute of Science| India | Nanjing University| China | University of Indonesia| Indonesia | University of the Philippines| Philippines

List of major Societies related to Oncology in the USA:

American Association of cancer research | American Board of Preventive Medicine (ABPM) | American College of Epidemiology | American Heart Association Council on Epidemiology and Prevention | American Public Health Association | American Society of Preventive Oncology | Association for Professionals in Infection Control Control and Epidemiology Inc.American Statistical Association (ASA)| Section on Statistics in Epidemiology (SIE)| Association for Prevention Teaching and Research (APTR)Canadian Society for Epidemiology and Biostatistics| Council of State and Territorial Epidemiologists (CSTE) Health Monitoring Systems| Inc.| International Clinical Epidemiology Network (INCLEN)| International Epidemiological AssociationInternational Society for Environmental Epidemiology (ISEE) | International Society for Pharmacoepidemiology| Netherlands Epidemiological SocietyAmerican Academy of Pediatrics| Section on Epidemiology| Society for Clinical Trials| Inc. | Society for Healthcare Epidemiology of America



List of major Societies related to Oncology in Europe:

European Oncology Nursing Society (EONS) |European Society for Medical Oncology (ESMO)  British Association for Cancer Research (BACR) | Association for International Cancer Research (AICR) European School of Oncology (ESO) | International Epidemiological Association  International Society for Environmental Epidemiology (ISEE)  | International Society for Pharmacoepidemiology | SGMO Swiss Society for Medical Oncology

List of major Societies related to Oncology in Asia:

Chinese Society of Clinical Oncology | Association of Oncology Social Work (AOSW) | Association of Pediatric Hematology Oncology Nurses (APHON) Association of Pediatric Oncology Social Work (APOSW) Health Monitoring Systems, Inc. International Clinical Epidemiology Network (INCLEN) | International Epidemiological Association | International Society for Environmental Epidemiology (ISEE) |http://immuno-oncology.euroscicon.com Association of Radiation Oncologists of India |  Japanese Breast Cancer Society |  Asian Cancer Foundation |  Japan Lung Cancer Society | Cancer Relief Society Nepal

List of major Conferences related to Oncology  in the USA:

Oncology Conferences USA 2018;; Oncology Conferences Canada 2018; Oncology Conferences Japan 2018;; Cancer Conferences Japan 2018; International Cancer Imaging Conferences October 2-4 | Oncology Conference USA, 2018 | 8th International EMT Meeting, Texas, US | Cancer Epigenetics: New Mechanisms, New Therapies, Colorado, US | WCC-2017 World Cancer Conference, Chicago, US | Cancer Imaging and Therapy, Florida, US

List of major Conferences related to Oncology in Europe:

9thWorld Biomarkers Conferences December 07-08, 2017 Madrid, Spain 12th World Hematology Conferences March 15-16, 2018 London, UK | 7th World Breast Cancer Conferences May 10-11, 2018 Frankfurt, Germany | 2nd International Epigenetics Conferences and Chromatin Conferences November 06-08, 2017 Frankfurt, Germany | 27thInternational Oncology research Conferences and Cancer Stem cells Conferences May 10-12, 2018 Frankfurt, Germany | International Oncology Conferences and Cancer Diagnosis Conferences August 28-30, 2017 Brussels, Belgium |  Oncology Conferences Asia 2018  20thEurope Cancer Therapy Conferences and Radiation Oncology Conferences August 28-29, 2017 Brussels, Belgium  25th World Cancer Conferences October 19-21, 2017 Rome, Italy |  Global Cancer Therapy Conferences August 07-09, 2017 Frankfurt, Germany |  In vivo model of metastasis Conferences   November 27-29, 2017 Berlin, Germany European Cancer Conferences September 7-9, 2018 Vienna, Austria |  9th European Urological Cancer Conferences November 16-19, 2017 Barcelona, Spain

List of major Conferences related to Cancer Sciences in Asia:

ESMO Summit Middle East, 2018 | ESMO Asia 2107 Congress, Singapore | Frontiers in Cancer Science 6-8th November 2017, Singapore | Indo-Oncology Summit-2018, India |  Cold Spring Harbor Asia conference on Precision Cancer Biology |  From Targeted to Immune Therapies, China | Asia Lung Cancer Summit in Hong Kong Targets Precision Medicine , Hong Kong  Frontiers in Cancer Science-2017, Singapore 3rd Multidisciplinary Lung Cancer Conference-2017, Singapore | 13th National Conference of the Asian Clinical Oncology Society, Thailand –

List of major Journals related to  Oncology in the USA:

Cancer Cell | Journal of Clinical Oncology | Journal of the National Cancer Institute | Clinical Cancer Research | Stem Cells Cancer | Molecular Cancer Therapeutics | International Journal of Radial Oncology Biology Physics | Journal of the National Comprehensive Cancer Network | Advances in Cancer Research | Oncotarget | Journal of Cancer Survivorship | Cancer Prevention Research | Seminars in  Oncology | Annals of Surgical Oncology | Seminars in Radiation  oncology | Journals of Thoracic Oncology | Current Opinion in Oncology | Cancer Control | Cancer Cytopathology

List of major Journals related to Cancer Sciences in Europe:

Lancet Oncology | Drug Resistance Updates | Breast Cancer Research | European Journal of Cancer | Nature Reviews Clinical Oncology | British Journal of Cancer | Blood Reviews  | Molecular Cancer | Endocrine-Related Cancer | Psycho-Oncology | Pigment Cell and Melanoma Research | Cancer Science | Environmental Carcinogenesis and Ecotoxicology Reviews Journal of Hematology and Oncology

List of major Journals related to Oncology in Asia:

Asian Pacific Journal of Cancer Prevention | Asian Pacific Journal of Cancer Prevention | The Japanese Association of Medical Sciences | Angiogenesis in Multiple Myeloma: Implications in Myeloma Therapy Lymphoma in Asia | Arsenates in the Treatment of Hematological Malignancies Endoscopic Diagnosis and Treatment for Early Gastric Cancer | Asia Pacific Journal of Public Health | Liver Cancer

List of jobs related to Oncology :

Nanoscience Faculty | Postdoctoral Position | Tenure-track Assistant Professor | Assistant/Associate/Full Professor - Physiology and Biophysics | Postdoctoral Associate | Associate/Full Professor of Oral Biology | Postdoctoral Fellow in Cancer Biology Environmental Epidemiologist | Assistant Professor Biology | Postdoctoral Research Fellow | Postdoctoral Fellow in cancer metabolism | Faculty Positions in Translational Sensory Neuroscience and Cancer | Postdoctoral Positions in Immunology | Cancer Immunologist & System biologist | Assistant Professor In Developmental Genetics | Research Technician | Principal Research Technician | Equipment Management Associate | Senior Research Tech | Senior Scientist Animal Research Technician | Senior Research Funding Manager | Senior Medical Writer | Research Assistant Molecular Field Applications Specialist | Lead Scientist – Immunochemistry | Senior Research Technician | Scientific Project Manager | Editorial Associate Director Senior Biomedical ScientistMolecular Profiling | Clinical Scientist/NGS Data Analyst | Field Application Scientist | Senior Cancer Analyst | Senior Translational Scientist | Clinical Laboratory Processing Technician | Principal Medical Writer | Product Manager | Product Support Scientist | Senior Quality Assurance Officer | Data Scientist – Bioinformatics | Research Scientist – Bioinformatics Senior Principal Upstream Process Development Scientist | Senior Cancer Analyst | Cell Line Development Scientist | Associate Principal Scientist

Past Conference Report

We gratefully thank all our wonderful Speakers, Conference Attendees, Students, Media Partners, Associations and Exhibitors for making Oncology and Immuno Oncology 2018 Conference the successful!

1st Edition of World Congress on Oncology and Immuno Oncology 2018, hosted by the Euroscicon Ltd. was held during July 23-24, 2018 at HYATT PLACE, Amsterdam, the Netherlands based on the theme “The Current Advancements in Oncology and Immuno Oncology" which got the magnificent response. With the support and guidance of Organizing Committee Members and Editorial Board Members and astonish presentations of all participants along with Scientists, Researchers, Students and leaders from various fields of Oncology made this event a grand success. 

Euroscicon Ltd expresses its gratitude to the conference Moderator, namely Dr Mohamed Mostafa Rizk, University of Alexandria, Egypt for taking up the responsibility to coordinate during the sessions for the smooth functioning of this event. We are indebted to your support. A very special thanks to our Exhibitors and Sponsors to have bestowed and their faith and invested in us to make this event a fruitful one. We hope you continue your support in our future endeavours. The conference was initiated with the Honourable presence of the Keynote forum. The speaker's list includes: 

  • Dr. Weisi Yan, University of South Alabama, USA
  • Dr. Donglu Shi, University of Cincinnati, USA
  • Dr. Igor Smit, Ijsselland Ziekenhuis, Netherlands
  • Dr. Kenji Ohe, Fukuoka University, Japan
  • Dr. Dwayne N. Jackson, University of Western Ontario, Canada
  • Dr. Mohamed Mostafa Rizk, University of Alexandria, Egypt
  • Dr. Jiangwen Zhang, University of Hong Kong, Hong Kong
  • Dr. María del Rosario Davalos Gamboa, University of San Simon, Bolivia
  • Dr. Jose Antonio Matute Briceno,  Sonora Cancer Research Center-Cics USA, Mexico
  • Dr. Wassil Nowicky, Ukrainian Anti-Cancer Institute, Austria
  • Dr. Mohammed Y Almaghrabi, Jing Abdullah Medical City, Kingdom of Saudi Arabia
  • Dr. Jan Jacques Michiels, Goodheart Institute and Foundation in Nature Medicine & Health, Netherlands
  • Dr. Kamlesh Guleria, Guru Nanak Dev University, India
  • Dr. Adnan Yousif Rojeab, London College UCK, U.K
  • Dr. Marjan Jalalimehr, Razi Institute, Iran
  • Dr. George Kunudji, Bikbok Herbal Centre, Ghana
  • Dr. Jana Slobodníkova, Alexander Dubcek University of Trencin, Slovakia
  • Dr. Dina Ron, Israel Institute of Technology, Israel

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

  • Immuno-Oncology Studies
  • Oncology
  • Clinical Oncology
  • Tumor Immunology
  • Types Of Cancer
  • Cancer Research & Cancer Vaccines
  • Antibody Therapy Of Cancer
  • Combining Cancer Immunotherapies
  • Immune Checkpoint Inhibitors
  • Radiology And Imaging In Cancer
  • Cancer Prognosis & Diagnosis
  • Cancer Micro And Immuno Environment
  • Stem Cell Therapy
  • Biomarker And Drug Targeting
  • Cancer Pharmacology
  • Cancer Biomarkers
  • Cancer Genomics And Metabolomics
  • Immuno-Oncology Studies
  • Cancer & HIV
  • Neuro Immunology
  • Tumour Immunotherapy Research
  • Radiation Oncology

Euroscicon Ltd also took the privilege of felicitating Oncology and Immuno Oncology 2018 Organizing Committee, Editorial Board Members of Archives in Cancer Research, Keynote Speakers, Chair and Co-Chairs, Moderator and Exhibitor who supported this event. With the grand success of Oncology and Immuno Oncology 2018, Euroscicon Ltd is proud to announce the 2nd Edition of World Congress on Immunology & Oncology 2019to be held soon.

More details visit: https:// immuno-oncology.euroscicon.com/2018

Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker


A huge thanks to all our amazing partners. We couldn’t have a conference without you!